Psychotropic drug use in Italy, 1984-99: The impact of a change in reimbursement status

International Clinical Psychopharmacology

Volumn 16, Issue 4, 2001, Pages 227-233

  Barbui, C ^a   Campomori, A ^b   Mezzalira, L ^c   Lopatriello, S ^c   Da Cas, R ^d   Garattini, S ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b CeVEAS   (Italy)

^c Osservatorio Farmaci SIFO   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Antidepressants; Antipsychotics; Benzodiazepines; Prescriptions; Psychotropic drugs

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; LORAZEPAM; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; DRUG USE; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REIMBURSEMENT;

EID: 0034957040     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200107000-00007     Document Type: Article

References (51)

1. Evolution of antidepressant drug consumption in Spain. The impact of selective serotonin re-uptake inhibitors
2. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability
3. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: A meta-analysis
4. Reimbursement changes for Italy
5. Randomised controlled trial of reminders to enhance the impact of audit in general practice on management of patients who use benzodiazepines
6. Hospital use of antipsychotic agents in 1989 and 1993: Stable dosing with decreased length of stay
7. Antidepressant drug use since the introduction of SSRI: National trends, regional differences, and impact on suicide rates
8. Clinical trials of new antipsychotics: A critical appraisal
9. A cross-sectional audit of benzodiazepine use among general practice patients
10. Quetiapine for schizophrenia. Commentary
11. Amitriptyline versus the rest: Still the leading antidepressant after 40 years of randomised controlled trials
12. Drug policy - From chaos towards cost-effectiveness
13. Benzodiazepine overprescribing: Successful initiative in New York State
14. Atypical antipsychotics: Part II: Adverse effects, drug interactions, and costs
15. Antipsychotics: Past and future National Institute of mental health division of services and intervention research workshop, July 14, 1998
16. The efficacy of drug treatments for dysthimia: A systematic review and meta-analysis
17. Olanzapine for schizophrenia
18. North of England evidence-based guideline development project: Summary version of guidelines for the choice of antidepressants for depression in primary care
19. Patterns of neuroleptic drug prescription: A national cross-sectional survey of a random sample of French psychiatrists
20. Antidepressant agents: From tricyclics to serotonin reuptake inhibitors
21. Senza la CUF il farma-caos. II Sole 24
22. Cultural shift in Italy's drug policy
23. Pharmaceutical prescriptions in four European countries
24. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis
25. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia
26. Selective serotonin reuptake inhibitors have broadened the utilisation of antidepressant treatment in accordance with recommendations. Findings from a Swedish prescription database
27. Drug prescribing for schizophrenic out-patients on depot injections. Repeat surveys over 18 years
28. Clozapine for the treatment-resistant schizophrenic
29. Risperidone versus typical antipsychotic medication for schizophrenia
30. Use and abuse of benzodiazepines in Hong Kong 1990-1993 - The impact of regulatory changes
31. Benzodiazepine substitution in medical practice. Analysis of pharmacoepidemiological data based on expert interviews
32. Pattern of prescriptions for neuropsychopharmaceuticals to first-admission schizophrenic patients in the county of Aarhus
33. Risperidone: How good is the evidence for efficacy?
34. SAMe for depression
35. Commissione Unica del Farmaco. Programma di revisione per il biennio 2000-2001 di medicinali registrati da più di 10 anni ai sensi dell'art. 4 della legge 14 Ottobre 1999, no. 362
36. Reduced prescription of benzodiazepines preparations n general practice. Much to gain with little effort
37. Use of new antidepressive agents in general practice
38. General practitioners prescribe more and more antidepressive agents. Repeated studies of prescriptions in a small municipality
39. Health care costs of therapy-refractory schizophrenic patients treated with clozapine: A study in community psychiatric service in Italy
40. Clinical and biologic response to clozapine in patients with schizophrenia
41. A comparison of clozapine and haloperidol in hospitalised patients with refractory schizophrenia
42. Changes in the pattern of antidepressant use upon the introduction of the new antidepressants: A prescription database study
43. New antipsychotics in the treatment of schizophrenia. A European survey
44. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine versus tricyclic antidepressants
45. Quetiapine for schizophrenia
46. Extent and appropriateness of benzodiazepine use. Results from an elderly urban community
47. Amitriptyline: Still efficacious, but at what cost?
48. Newer atypical antipsychotic medication versus clozapine for schizophrenia
49. Usage patterns of benzodiazepines in a Dutch community: A 10-year follow-up